PMID- 12113052
OWN - NLM
STAT- MEDLINE
DCOM- 20020815
LR  - 20191210
IS  - 1473-7140 (Print)
IS  - 1473-7140 (Linking)
VI  - 2
IP  - 3
DP  - 2002 Jun
TI  - Treatment of refractory and relapsed acute myelogenous leukemia.
PG  - 287-95
AB  - Refractory and relapsed disease occurs in most acute myelogenous leukemia 
      patients. Salvage chemotherapy offers a 30-70% chance of a second complete 
      remission. Unfortunately, this second remission is usually short lived and 
      salvage chemotherapy is rarely curative. Allogeneic bone marrow transplant, 
      either human leukocyte antigen (HLA)-sibling matched or matched unrelated donor, 
      is the only treatment to offer long-term disease-free survival and possible cure. 
      Many patients will be ineligible for allogeneic bone marrow transplant. A 
      conjugated antiCD33 monoclonal antibody, gemtuzumab ozogamicin, has recently been 
      approved for use in relapsed and refractory acute myelogenous leukemia patients. 
      New and novel agents are also undergoing trials in an attempt to improve on the 
      overall poor outcomes.
FAU - Stanisic, Slobodan
AU  - Stanisic S
AD  - Cleveland Clinic Foundation, Department of Hemotology and Medical Oncology, 9500 
      Euclid Ave. R-35, Cleveland, OH 44195, USA. Staniss@ccf.org
FAU - Kalaycio, Matt
AU  - Kalaycio M
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Anticancer Ther
JT  - Expert review of anticancer therapy
JID - 101123358
RN  - 0 (Aminoglycosides)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drugs, Investigational)
RN  - 93NS566KF7 (Gemtuzumab)
SB  - IM
MH  - *Aminoglycosides
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Antibodies, Monoclonal/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/*therapeutic use
MH  - *Bone Marrow Transplantation/methods
MH  - Disease-Free Survival
MH  - Drugs, Investigational/therapeutic use
MH  - Gemtuzumab
MH  - Humans
MH  - Leukemia, Myeloid, Acute/mortality/*therapy
MH  - Recurrence
MH  - Remission Induction
MH  - Salvage Therapy/methods
MH  - Transplantation, Autologous
MH  - Transplantation, Homologous
RF  - 61
EDAT- 2002/07/13 10:00
MHDA- 2002/08/16 10:01
CRDT- 2002/07/13 10:00
PHST- 2002/07/13 10:00 [pubmed]
PHST- 2002/08/16 10:01 [medline]
PHST- 2002/07/13 10:00 [entrez]
AID - ERA020307 [pii]
AID - 10.1586/14737140.2.3.287 [doi]
PST - ppublish
SO  - Expert Rev Anticancer Ther. 2002 Jun;2(3):287-95. doi: 10.1586/14737140.2.3.287.